Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Moving toward cash flow positivity in 2022 with accelerating reimbursement activity
- Net sales amounted to 13,7 MSEK (10.9), an increase of 25 percent over the same period 2020.
- Operating result amounted to -13.6 MSEK (-9,5)
- Net result after financial items amounted to -13.9 MSEK (-9.9)
- Earnings per share were -0,21 SEK (-0,18)
- Cash Balance amounted to 21.0 MSEK (14.8)
- Average Daily Treatment Revenue (ADTR)* was 147 TSEK (99), an increase of 47 percent over the same period in 2020.
- Net sales amounted to 40.9 MSEK (33.7), an increase of 21 percent over the same period 2020.
- Operating result amounted to - 30.1 MSEK (-30.9)
- Net result after financial items amounted to -31.2 MSEK (-32.1)
- Earnings per share were -0,48 SEK (-0,58)
- Cash Balance amounted to 21.0 MSEK (14.8)
- Average Daily Treatment Revenue (ADTR)* was 146 TSEK (104), an increase of 40 percent over the same period in 2020.
- Dignitana AB announced in October that the CFO will leave the Company.
- Dignitana announced sponsorship of the world's leading breast cancer organization, Susan G. Komen®, with DigniCap presence at three signature events in California and Florida.
- In July Dignitana signed distributor B&Co Group to support growth in Benelux.
- The Board of Directors has appointed The Chairman of the Board Klas Arildsson to the role of a working Chairman supporting growth from an operational point of view. He will focus on Quality and Regulatory Affairs and operational efficiency
- Dignitana announced a decision from Medicare enabling reimbursement to cancer centers providing DigniCap to chemotherapy patients in the US effective January 1, 2022.
- Five DigniCap patients were recognized as DigniCap Dignitaries during Breast Cancer Awareness month and interviewed in weekly Facebook Live broadcasts in October.
Key Figures
DIGNITANA GROUP Q3 Q3 Q1-Q3 Q1-Q3 2020 Full year 2020
2021 2020 2021
Net sales, TSEK 13,657 10,884 40,860 33,701 46,629
Total revenues, TSEK 13,723 12,596 45,054 36,950 49,956
Net profit after -13,916 -9,859 -31,240 -32,142 -52,963
financial items, TSEK
Cash and bank balances, 21,047 14,796 21,047 14,796 78,770
TSEK
Earnings per share -0.21 -0.18 -0.48 -0.58 -0.96
before and after
dilution, SEK
Average Daily Treatment 147 99 146 104 120
revenue*, TSEK
* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
"I firmly believe that we have made the right choices and realigned our organization to take the next step towards attaining our long-awaited goal of cash flow positivity." -William Cronin, CEO Dignitana AB
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-11-2021 08:00 CET.